The St. Joseph-based systems biology technology provider GeneGo Inc. Thursday announced that it has integrated GenomeQuest’s Sequence Data Management platform with GeneGo’s MetaCore and MetaDrug.
Using GenomeQuest’s interactive analysis, scientists who have drilled down to a list of particular genes of interest (hundreds of millions of reads, to thousands of expressed genes, to dozens or more of particular genes of interest) can now seamlessly pass that gene list along with their associated expression values to the GeneGo suite of pathway analysis software tools.
“The ability to analyze hundreds of datasets, reducing millions of reads down to a shorter list of particular genes of interest, and then being able to visualize where those genes are active in specific (potentially disease-related) pathways, is a significant accomplishment,” said Don Gregory, director of field application science for Westborough, Mass.-based GenomeQuest. “Scientists will be able to quickly focus on their scientific questions, rather than manipulating large reads datasets and lists of thousands of genes. We believe this will enhance discovery throughout the genomics and proteomics research pipelines.”
Added Julie Bryant, vice president of business development at GeneGo:
“This integration will allow our joint customers to seamlessly work with NGS data in the context of pathways. The integrated workflows will lead our users from raw sequence runs to functional hypothesis generation of drug targets and biomarkers. With NGS data picking up steam in translational medicine and individual healthcare, this integration will help us to leverage our unique disease pathology maps developed in our MetaMiner programs in oncology, CNS, metabolic, respiratory diseases and other therapeutic areas.”
GeneGo develops systems biology technology such as compound based pathway analysis, cheminformatics and bioinformatics software for life science research. The original computational MetaDiscovery platform allows an integration and expert analysis of different kinds of experimental data and relevant bioactive chemistry within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 6.3, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.3, is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds.
More at www.genego.com.
(c) 2010, WWJ Newsradio 950. All rights reserved.